$KLRS News
Last published 3d ago
- 3d agoKLRSKalaris Therapeutics, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 3d agoKLRSKalaris Reports Third Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswirePreliminary data from the ongoing Phase 1b/2 study of TH103 in nAMD is now expected in 2H 2027
- 2mo agoKLRSKalaris to Present at Morgan Stanley 24th Annual Global Healthcare ConferenceGlobeNewswireBERKELEY HEIGHTS, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ:KLRS) ("Kalaris"), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of
- 3mo agoKLRSKalaris Reports Second Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewswirePatient dosing is ongoing in the Phase 1b/2 study of TH103; preliminary data anticipated in 1H 2027 Potential Phase 3 clinical trials remain on track for initiation by year-end 2027 $93.5 million in cash, cash
- 3mo agoKLRSALVRKLRS: Abbott Cooper PLLC Announces Investigation on Behalf of Kalaris Therapeutics, Inc. (Formerly Allovir, Inc.) StockholdersGlobeNewswireSTAMFORD, Conn., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Abbott Cooper PLLC is investigating potential legal claims on behalf of stockholders of Kalaris Therapeutics, Inc. (NASDAQ:KLRS), formerly AlloVir, Inc.
- 3mo agoKLRSKalaris Expands Leadership Team Appointing Liisa Bayko as Chief Financial OfficerGlobeNewswireStrategic finance leader with over 20+ years of experience in the biotechnology space CFO hire bolsters Kalaris’ leadership team and supports continued growth of the company as it enrolls its Phase 1b/2 study of TH103
- 3mo agoKLRSKalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD CohortsGlobeNewswireData from the expanded cohorts reinforce the positive BCVA, OCT, pharmacokinetic and time-to-retreatment findings observed in the original cohorts Enrollment in the Phase 1b/2 multiple-ascending dose trial of TH103
- 4mo agoKLRSPEPGIMRXKalaris Appoints Laurie Keating to Board of DirectorsGlobeNewswireBERKELEY HEIGHTS, N.J., July 06, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ:KLRS) ("Kalaris"), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of
- 4mo agoKLRSKalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively EnrollingGlobeNewswireBERKELEY HEIGHTS, N.J., June 23, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ:KLRS) ("Kalaris"), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of
- 5mo agoKLRSKalaris to Present at Clinical Trials at the Summit 2026GlobeNewswireBERKELEY HEIGHTS, N.J., June 12, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ:KLRS) ("Kalaris"), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of
- 6mo agoKLRSKalaris Reports First Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewswirePatient screening now underway in the Phase 1b/2 study with the latest drug product batch on track to be available to support upcoming dosing; preliminary data anticipated in 1H 2027 Planned Phase 3 clinical trials
- 9mo agoKLRSKalaris to Present Phase 1 Clinical Data for TH103 at the Macula Society Annual MeetingGlobeNewswireBERKELEY HEIGHTS, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ:KLRS) ("Kalaris"), a clinical-stage biopharmaceutical company developing differentiated therapies for retinal diseases, today
- 11mo agoKLRSKalaris Therapeutics Announces Oversubscribed $50.0 Million Private PlacementGlobeNewswireBERKELEY HEIGHTS, N.J., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ:KLRS) ("Kalaris"), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of
- 11mo agoKLRSKalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMDGlobeNewswireTH103 showed mean 10-letter gain in visual acuity and rapid, robust anatomic improvement at Month 1, following a single injection TH103 was generally well tolerated, supporting further dose escalation beyond 2.5 mg
- 1y agoKLRSKalaris Reports Third Quarter 2025 Financial Results and Provides Business UpdatesGlobeNewswirePhase 1a Single Ascending Dose trial remains on track for initial clinical data to be reportedby year end 2025 Phase 1b/2 Multiple Ascending Dose trial currently enrolling, intended to inform dose selection for
- 1y agoKLRSKalaris Expands Leadership Team Appointing Matthew Gall, MBA, as Chief Financial OfficerGlobeNewswireHighly experienced biopharma financial officer joins leadership team CFO hire bolsters Kalaris' leadership team and supports continued growth of the company as it enrolls its Phase 1b/2 study in treatment naïve nAMD
- 1y agoKLRSKalaris to Present at Stifel 2025 Annual Healthcare ConferenceGlobeNewswirePALO ALTO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ:KLRS) ("Kalaris"), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for
- 1y agoKLRSUPDATE – Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular DegenerationGlobeNewswireRecently initiated Phase 1b/2 multiple ascending dose study intended to assess safety and efficacy in nAMD patients receiving four initial monthly doses of TH103 Phase 1b/2 study to inform dose selection for potential
- 1y agoKLRSKalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular DegenerationGlobeNewswireRecently initiated Phase 1b/2 multiple ascending dose study intended to assess safety and preliminary efficacy in nAMD patients receiving up to four initial monthly doses of TH103 Phase 1b/2 study to inform dose
- 1y agoKLRSKalaris Reports Second Quarter 2025 Financial Results and Provides Business UpdatesGlobeNewswireContinuing to enroll nAMD patients in a Phase 1 trial of TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovascular and exudative
- 1y agoKLRSKalaris to Present at Noble Capital Markets 2025 Emerging Growth Equity ConferenceGlobeNewswirePALO ALTO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ:KLRS) ("Kalaris"), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for
- 1y agoKLRSKalaris to Participate at Stifel Ophthalmology ForumGlobeNewswirePALO ALTO, Calif., May 23, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ:KLRS) ("Kalaris"), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for
- 1y agoKLRSKalaris Reports First Quarter 2025 Financial Results and Provides Business HighlightsGlobeNewswireActively enrolling nAMD patients in a Phase 1 trial of TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovascular and exudative
- 1y agoKLRSKalaris Expands Board of Directors Appointing Leone Patterson as Chair of Audit CommitteeGlobeNewswirePALO ALTO, Calif., April 04, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ:KLRS) ("Kalaris"), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments
- 1y agoKLRSKalaris Announces Closing of Merger with AlloVirGlobeNewswireKalaris is focused on developing TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovascular and exudative diseases of the retina